Navigation Links
Ansell Healthcare Receives CE Mark for GAMMEX® Powder-Free Gloves With AMT Antimicrobial Technology
Date:10/17/2011

BRUSSELS, October 17, 2011 /PRNewswire/ --

Novel Gloves First to be Classified as Class III Medical Devices

Ansell Healthcare, a global leader in healthcare barrier protection, announced today that it has received the CE Mark for GAMMEX® Powder-Free gloves with AMT Antimicrobial Technology. Through its unique virus and bacteria-killing technology, the novel GAMMEX® Powder-Free with AMT provides protection against some of the most common pathogens and drug-resistant bacteria in the event of a glove breach*. Ansell will commercially launch GAMMEX® Powder-Free gloves with AMT across Europe in the autumn of 2011.

"We look forward to bringing a new level of protection and peace of mind to the surgical staff," said Peter Dobbelsteijn, Senior Vice President EMEA, Ansell Healthcare. "GAMMEX® Powder-Free with AMT has its own immune system to fight back against pathogens that migrate through the breaches that inevitably occur in actual use."

The gloves, made of natural rubber latex, provide the same feel, sensitivity, flexibility and dexterity as conventional gloves when manipulating and handling instruments. The main difference is the active antimicrobial layer which contains chlorhexidine gluconate (CHG). This proprietary technology can provide ongoing antiviral and antibacterial protection against HIV, hepatitis C and infectious bacteria.

"The new GAMMEX® Powder-Free with AMT is a significant technical breakthrough in terms of bringing about a change from passive protection to active protection. These new gloves respond to the demands of healthcare workers in the surgical theatre who face infection risks every day. With AMT Antimicrobial Technology, we can offer healthcare workers an extra level of security. Glove breaches happen during surgery through the use of sharp instruments and with the AMT technology, Ansell provides for a backup plan," said David Lucas, Vice President Science & Technology, Ansell Healthcare.

Receiving the CE Mark is a major milestone in the process of bringing this groundbreaking technology to the European market.

* In clinical and laboratory tests, GAMMEX® Powder-Free with AMT killed at least 99% of invading HIV and HCV (hepatitis C) surrogate pathogens, the two main viruses that concern surgeons. In addition, clinical testing has shown that the gloves kill over 99.7% of eight common infectious bacteria (gram-positive, gram-negative and drug-resistant bacteria) and kill over 99.99% of staphylococcus aureus.

GAMMEX® Powder-Free Gloves with AMT Antimicrobial Technology are not proven to protect against blood-borne infections where the skin is broken, cut or punctured.

GAMMEX® Powder-Free Gloves with AMT Antimicrobial Technology contain natural rubber latex, which may cause allergic reactions.

Australia Patent No. 703926 and New Zealand Patent No. 556353. AU and worldwide patents pending.

Ansell, ® and ™ are trademarks owned by Ansell Limited or one of its affiliates.

© 2011 Ansell Limited. All rights reserved.

About Ansell

Ansell is a world leader in providing superior health and safety protection solutions that enhance human well being. With operations in North America, Latin America, EMEA and Asia, Ansell employs more than 10,000 people worldwide and holds leading positions in the natural latex and synthetic polymer glove and condom markets. Ansell operates in four main business

segments: Medical Solutions, Industrial Solutions, New Verticals and Sexual Wellness. Information on Ansell and its products can be found at http://www.ansell.eu

For the press pack and photographs, please click here: http://www.anselleurope.com/medical/index.cfm?page=gammex_pf_amt&lang=EN

 



'/>"/>
SOURCE Ansell Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. ViroPharma to Present at Three Upcoming Healthcare Conferences
5. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
6. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
7. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
8. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
9. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
10. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... "Company") (NASDAQ: UNIS ; ASX: UNS), a developer and ... for the second quarter of fiscal 2016 (three months ended December ... Financial Results for the Second Quarter of Fiscal 2016 ... the second quarter of fiscal 2016 was $4.5 million, compared to ... customers for the second quarter of fiscal 2016 were $17.8 million, ...
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Hearing protection devices refer to the barriers that reduce ... ear. Hearing protection devices include earplugs, uniform attenuation earplug, ... users exposed to noise levels of over 80 dB ... inserted in the ear canal to protect the ear. ... sound perception with the help of acoustic filters. Earmuffs ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... ... ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited a home ... any heat. Shortly after entering the home, Paul was able to identify the problem ... carbon monoxide into the home, at 2,000 parts per million in the flue. Anything ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. ... department stores, announced it has raised $176,000 to benefit the Breast Cancer Research ... Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, and ...
Breaking Medicine News(10 mins):